Current and emerging approaches to noncompetitive AR inhibition.
Sign Up to like & getrecommendations! Published in 2023 at "Medicinal research reviews"
DOI: 10.1002/med.21961
Abstract: The androgen receptor (AR) has been shown to be a key determinant in the pathogenesis of castration-resistant prostate cancer (CRPC). The current standard of care therapies targets the ligand-binding domain of the receptor and can… read more here.
Keywords: emerging approaches; inhibition; noncompetitive inhibition; approaches noncompetitive ... See more keywords